Why Pectuslab Devices Are Different: R&D, Clinical Review and Lifelong Support
Why Pectuslab Devices Are Different: R&D, Clinical Review and Lifelong Support
Non-surgical approaches to chest wall deformities (pectus carinatum, pectus excavatum, rib flare) have been described in the literature for many years, and what these methods have in common is that they work best not as a single device, but as part of a long-term process that requires consistent follow-up. A review of vacuum bell therapy notes that the device has become an established alternative in selected patients, though long-term outcomes are still being evaluated in the literature [1]. Similarly, a study examining the factors that affect patient compliance with brace therapy found that treatment success depends heavily on consistent use and follow-up [2].
When these two findings are taken together, a clear picture emerges: in conservative treatment, what matters most is not the moment the device leaves the box, but how much support the patient and family receive afterward. This is exactly where Pectuslab's approach sets itself apart: product development is treated as an integrated responsibility that continues after the sale, not one that ends with it.
This detail matters especially for patients who are still growing: conservative treatment for chest wall deformities typically unfolds over years rather than months, and throughout that time both the device and the team guiding the patient need to stay reliably engaged. The longer treatment continues, the more important it becomes to design the product not simply as "something purchased," but as part of a service that accompanies the patient throughout the process.
This approach is part of Pectuslab's everyday practice - it shapes how every product is developed, clinically reviewed, and supported long after it reaches a patient.
1. Product Development: Not Just Manufacturing, But a Process Grounded in the Literature
Creating a brace or a vacuum bell device is not simply a matter of selecting materials and producing a mold. Devices used to treat chest wall deformities must account for many variables: the flexibility of the growing rib cage, the type and severity of the deformity, the patient's age, and day-to-day comfort during use. At Pectuslab, product development weighs these variables alongside the general principles found in conservative treatment approaches - such as gradual pressure/compression logic and the need for anatomical fit - as part of a multi-stage, tightly controlled development and production process.
Specific manufacturing steps or internal process details are not shared at this stage - this is less a matter of commercial sensitivity than a deliberate separation between the information patients and families actually need (how to use the product, why this approach was chosen) and technical production information. What matters to families is not the order in which a product is manufactured, but the standard it has met by the time it reaches them.
This process is not limited to a one-time design exercise. Publications and clinical feedback in the field of conservative treatment accumulate over time; when a new finding emerges or a recurring usage issue is identified, that information feeds into reviewing existing products or guiding future development. In other words, product development does not end at launch - it remains an open loop for as long as the product stays in use.
2. Clinical Review: Before a Product Reaches the Field
A product that has completed development is not handed directly to patients; it is first reviewed in a clinical context. This review is meant to reveal how the product behaves under real-world conditions, which feedback stands out, and where improvement is needed. One point worth emphasizing here: this process is not carried out to publicly share individual patient outcomes or to claim a success rate - it exists to assess the product's fit for clinical practice.
The broader literature on conservative treatment methods supports this cautious approach. As with vacuum bell therapy, even though the method has been in use for years, the process of gathering long-term outcome data is still ongoing in the literature [1]; this places a responsibility on manufacturers to keep monitoring a product even after it reaches the market.
Clinical review also includes collaboration with specialist physicians in the field. The practical challenges a product encounters in everyday use - comfort, ease of adjustment, how clear the settings are - often become apparent through the observations of specialists working directly with patients; this feedback is folded into the general product improvement process without disclosing any patient's identity or individual outcome.
3. After the Device Reaches the Patient: A Multi-Year Technical Service Approach
At Pectuslab, the process does not end the moment the device leaves the box. In the Gvacuum product family, for example, a two-year warranty approach and support for replacement parts (such as the pump and tubing) serve as a reference point; the goal is to keep the device functional throughout a long treatment process. The same logic carries over to other product lines as technical service and maintenance support, with the aim of ensuring that a patient's treatment program is never interrupted by a minor issue with the device.
A clear distinction needs to be made here: technical service support is not a guarantee that the device will function without fault, nor that treatment will produce a certain outcome; what is offered is a service framework that covers maintenance and replacement-part needs throughout the device's working life.
In practice, this means that when wear appears over time, a part needs replacing, or a technical question comes up about use, the patient and family do not have to work it out on their own. They can reach the support line to report the issue, get guidance, and start a replacement-part or maintenance process when needed. The purpose of this continuity is to keep a technical issue with the device from disrupting the daily routine of treatment.
4. Clinical Support: Not Leaving Families and Patients on Their Own
Alongside technical service, the goal is also to provide ongoing answers to questions about the treatment process itself. Questions that come up during use, uncertainty about the device's settings, or everyday challenges that affect compliance are often issues that are not resolved in a single visit. Research examining the factors behind patient compliance points to the same thing: adherence to treatment is tied not just to having the device, but to the sense of guidance and support a patient receives throughout the process [2].
For this reason, Pectuslab's approach to clinical support is built as a communication channel that continues throughout treatment, not a relationship that ends at the point of sale. Whenever there is any question of diagnosis, a change in treatment, or a suspected complication, going directly to a specialist always takes priority; Pectuslab's support does not replace that specialist follow-up - it complements it.
5. Why Does It Matter That These Three Elements Come Together?
Bringing R&D, clinical review, and long-term after-sales support (both technical and clinical) together under one roof, without gaps, is not standard practice across the industry. Often, one or two of these elements stand out while the others lag behind; a company might have a strong R&D process but limited after-sales support, or the reverse. Pectuslab's positioning rests on treating these three elements not as separate pieces, but as parts of a single, continuous process.
In practical terms, this is simple: when a family acquires a product from Pectuslab, what stands behind it is not just a device, but a team that stands behind that device. This team understands the reasoning behind how the device was developed, knows how it was evaluated in a clinical context, and stays in contact after the device reaches the patient.
6. What Does This Approach Mean in Practice for a Family?
From a family's perspective, having R&D, clinical review and after-sales support work together in this way translates into a few concrete things. First, a product can be chosen by looking not only at its features, but at the support structure standing behind it. Second, for practical questions that may arise during treatment, families can rely on more than a one-time sales relationship. Third, when a technical need arises with the device, it is clear from the outset where to direct it.
Taken together, these three elements make it possible to see treatment not simply as a purchasing decision, but as a collaboration sustained over time. Pectuslab's positioning rests on this same framework: the product, its clinical context, and after-sales support are treated not as three disconnected items, but as parts of a single process.
Frequently Asked Questions
Does the multi-year technical service approach work the same way across all Pectuslab products? The underlying logic is the same, but the scope can vary by product family, since replacement parts are specific to each device; for current, product-specific information, it is best to contact the Pectuslab team directly.
Does clinical support mean a diagnosis or treatment decision? No. Clinical support covers general guidance and communication related to the course of use; for any diagnosis, change in treatment plan, or suspected complication, a specialist (a thoracic surgeon, pediatric surgeon, orthopedic specialist, or physical therapist) should always be consulted directly.
Does this approach mean treatment will be completed faster or with a more definite outcome? No. The integration of R&D, clinical review, and after-sales support is about continuity of service; it does not involve any commitment to a specific duration, outcome, or success rate. The course of treatment always depends on the individual patient's condition and specialist follow-up.
In the end, the product chosen for treating a chest wall deformity should be part of a process that continues after the purchase, not one that ends with it. Pectuslab's positioning - bringing together R&D, clinical review, and long-term technical and clinical support - reflects an effort to preserve exactly that continuity.
Sources
1. Haecker FM, Sesia S. "Vacuum bell therapy." Annals of Cardiothoracic Surgery. 2016;5(5):440-449. pmc.ncbi.nlm.nih.gov/articles/PMC5056932
2. Kang DY, Jung J, Chung S, Cho J, Lee S. "Factors affecting patient compliance with compressive brace therapy for pectus carinatum." Interactive CardioVascular and Thoracic Surgery. 2014;19(6):900-903. pubmed.ncbi.nlm.nih.gov/25164133
Sources
[1] Haecker FM, Sesia S. "Vacuum bell therapy." Annals of Cardiothoracic Surgery. 2016;5(5):440-449.
Contact Us
Have questions? Talk to our team about pectus treatment products and the right solution for you.
